Physician profile
Mathew E Bagamery
NPI 1174525182
$1,772.10
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $647 · 2020: $472 · 2021: $653.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $494.88 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $346.42 | 2019-2021 | |
| Abbvie INC. | $246.73 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $159.77 | 2019-2021 | |
| Braintree Laboratories, INC. | $60.75 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $54.57 | 2020-2021 | |
| Evoke Pharma, INC. | $52.31 | 2020-2021 | |
| Amgen INC. | $51.84 | 2021 | |
| Intercept Pharmaceuticals, INC. | $51.46 | 2019-2021 | |
| Janssen Biotech, INC. | $48.38 | 2020-2021 | |
| Qol Medical, LLC | $47.98 | 2020-2021 | |
| Endo Pharmaceuticals INC. | $45.76 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $30.34 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $29.37 | 2019-2020 | |
| Romark Laboratories, Lc | $22.93 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $17.21 | 2019 | |
| Daiichi Sankyo INC. | $11.40 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mathew Bagamery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.